फोसएम्प्रेनाविर और मैराविरोक का इंटरैक्शन

SELZENTRY is contraindicated in patients with severe renal impairment or ESRD (creatinine clearance [CrCl] less than 30 mL per minute) who are concomitantly taking potent CYP3A inhibitors or inducers [see Warnings and Precautions ( 5.3 )].

SELZENTRY is contraindicated in patients with severe renal impairment or end-stage renal disease (ESRD) (creatinine clearance [CrCl] less than 30 mL per minute) who are concomitantly taking potent CYP3A inhibitors or inducers.

• Coadministration with CYP3A inhibitors, including protease inhibitors (except tipranavir/ritonavir), will increase the concentration of SELZENTRY.

SELZENTRY should be used in patients with severe renal impairment or ESRD only if they are not receiving a concomitant potent CYP3A inhibitor or inducer.

The recommended dose of maraviroc is 150 mg twice daily when coadministered with fosamprenavir calcium/ritonavir.

Fosamprenavir calcium should be given with ritonavir when coadministered with maraviroc.

HIV CCR5 co-receptor antagonist: Maraviroc a Fosamprenavir calcium/ritonavir: ↓ Amprenavir ↑ Maraviroc No dosage adjustment required for fosamprenavir calcium /ritonavir.